SCHEMBL14249484

SCHEMBL14249484

O=C1CCCCn2cccc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.41
PDPK1 O15530 1/20 0.34
SOS1 Q07889 1/20 0.34
SOS2 Q07890 1/20 0.34
HDAC6 Q9UBN7 1/20 0.33
MAPT P10636 3/20 0.33
ALDH1A1 P00352 2/20 0.33
HSD17B10 Q99714 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
NPC1 O15118 2/20 0.32
GAA P10253 2/20 0.32
RAB9A P51151 2/20 0.32
USP2 O75604 1/20 0.32
NFKB1 P19838 1/20 0.32
NFKB2 Q00653 1/20 0.32
RELA Q04206 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
TLR9 Q9NR96 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1438872 0.94 ACHE (0.41) ACHESOS1SOS2HDAC6MAPT
SCHEMBL1438685 0.70
SCHEMBL1126763 0.68 KDM4E (0.51) MAPTALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL3022168 0.68 ALDH1A1 (0.35) PDPK1MAPTALDH1A1HSD17B10L3MBTL1
SCHEMBL14249861 0.67 CA1 (0.34) ACHESOS1SOS2MAPTHSD17B10
SCHEMBL15473984 0.67 CYP1A2 (0.36) CYP1A2
SCHEMBL21765805 0.66 ACHE (0.40) ACHEMAPTALDH1A1HSD17B10L3MBTL1
SCHEMBL14248892 0.65 BUB1 (0.33) MAPTALDH1A1HSD17B10MEN1KMT2A
SCHEMBL12810523 0.65 ACHE (0.33) ACHE
SCHEMBL14249410 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12410164-B2 Heterocyclic compounds and medical use thereof FONDAZIONE TELETHON (IT) 2025-09-09 US disclosed
US-11667643-B2 RIP1K inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2023-06-06 US disclosed
WO-2012172093-A1 DIHYDROINDOLIZINE DERIVATE AS METABOTROPIC GLUTAMATE RECEPTOR MODULATORS MERZ PHARMA GMBH & CO. KGAA (DE) 2012-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11667643-B2 RIP1K inhibitors RIPK1, RIPK2, RIPK3 ACHE 4664/4885PDPK1 49/4885SOS1 2385/4885
US-12410164-B2 Heterocyclic compounds and medical use thereof NPPA, NPR1, CYC1 ACHE 1359/4885PDPK1 3724/4885SOS1 1988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.